Loading patent…
AssigneeAblynx N.V.
InventorsJulie A. JAWORSKI, Sagar V. KATHURIA, Brian MACKNESS, Sunghae PARK, Victor Zhao SUN, Qun ZHOU
Estimating the term…
The present disclosure provides Fc domain variant polypeptides, including effector-competent Fc domain variants. The present disclosure also provides Fc domain variant polypeptides comprising at least one substitution or at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide. The present disclosure also provides nucleic acids encoding Fc domain variant polypeptides and host cells for making Fc domain variant polypeptides. Methods for increasing the yield of Fc domain variant polypeptides, and methods of using Fc domain variant polypeptides to treat disease, are also provided.
A Fc domain variant polypeptide, wherein the Fc domain variant polypeptide comprises at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide.
6-68. (canceled)
70-73. (canceled)
75-78. (canceled)
(canceled)
82-87. (canceled)
89-92. (canceled)
95-98. (canceled)
100-104. (canceled)
(canceled)
108-109. (canceled)
111-113. (canceled)
A pharmaceutical composition comprising a Fc domain variant polypeptide wherein the Fc domain variant polypeptide comprises at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide and a pharmaceutically acceptable carrier or diluent.
A nucleic acid molecule encoding a Fc domain variant polypeptide wherein the Fc domain variant polypeptide comprises at least two substitutions at amino acid positions 251, 267, 268, 298, 314, 330, 339, 373, and 376, according to EU numbering, as compared to a Fc domain parent polypeptide.
Dependencies are inferred from the claim text.